Market Overview

Valeant Had A 58% Chance Of Bankruptcy Last Year

Share:
Valeant Had A 58% Chance Of Bankruptcy Last Year
Related VRX
What Happens To A Stock When An Activist Liquidates A Position?
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook
Bill Ackman Finally Pukes: Beware of False Narratives (GuruFocus)
Related AGN
Buyback ETF Steady As Repurchases Decline
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Marketplace Roundtable: Biotech Hanging In The Balance (Seeking Alpha)

In a new report, Wells Fargo analyst David Maris slams Underperform-rated Valeant Pharmaceuticals Intl Inc (NYSE: VRX) because of a number of unanswered questions surrounding its business and balance sheet. After a horrendous several months, Wells Fargo is bullish on specialty pharmaceutical stocks as a whole, but Valeant is a strong exception.

In his report, Maris uses a balance sheet analysis technique called the Altman Z-score model, which was developed by Edward Altman in the 1960s as a way to measure the probability of bankruptcy.

According to Maris, an Altman Z-score below 1.8 is a signal of financial distress, and Valeant’s Altman Z-score has been below this threshold for each of the last five years. Valeant’s current score is only 0.79, which suggests a bankruptcy probability of 58.4 percent.

“While the Altman Z-score may produce false positives, its predictive accuracy is greater than 70% two years prior to bankruptcy,” Maris explains. “Even so, we consider this ratio as a signal for further questioning.”

Related Link: Market Bull: S&P 500 Could Fall More Than 30%

In addition to Valeant, Wells Fargo used Altman Z-scores to calculate the bankruptcy probabilities of Valeant’s pharma rivals as well. At 39.9 percent, Allergan plc Ordinary Shares (NYSE: AGN) was the only other name with a probability higher than 6.9 percent.

Benzinga reached out to Valeant but no one was available to comment on the report.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for VRX

DateFirmActionFromTo
Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Rodman & RenshawDowngradesBuyNeutral

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Short Ideas Health Care Rumors Analyst Ratings Movers Best of Benzinga

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!